Company news
Genedrive Plc (LSE:GDR) news
Genedrive Plc news releases on 6ix. Latest, Mar 27, 2025: RetailBook Offer
Press releases — page 2
RetailBook Offer
March 27, 2025
Scottish Government testing programme investment
March 17, 2025
CYP2C19-ID Kit adopted for routine clinical use
March 14, 2025
Genedrive® CYP2C19-ID Kit performance published
December 27, 2024
Grant of Options
December 20, 2024
Posting of annual report and notice of AGM
December 5, 2024
Block listing returns
November 29, 2024
NIHR and OLS Funding Package
November 21, 2024
Department for Business and Trade feature
November 5, 2024
Scottish Health Technology Group publications
November 4, 2024
Director Declaration
October 21, 2024
Director/PDMR Shareholding
August 15, 2024
First UK commercial sales of the CYP2C19-ID Kit
August 12, 2024
Directorate Change
August 6, 2024
NICE recommends CYP2C19-ID Kit in final guidance
July 31, 2024
Breakthrough Device Designation from the U.S. FDA
July 15, 2024
Short extension to NICE publication date
June 27, 2024
Result of Open Offer and REX Offer
May 30, 2024
Initial orders of the Genedrive MT-RNR1 Products
May 24, 2024
Key CYP2C19-ID test performance milestone achieved
May 21, 2024
Amendment to Open Offer timetable
May 15, 2024
Completion of placing
May 10, 2024
Proposed REX Retail Offer
May 9, 2024
Clinical Trial Agreement
April 24, 2024
NICE recommends the Genedrive CYP2C19-ID Kit
April 3, 2024
Half-year Report
March 28, 2024
Investor presentation
March 26, 2024
Receipt of R&D tax credit
March 15, 2024
NICE Early Value Assessment update
February 19, 2024
Total Voting Rights
February 2, 2024
Equity Prepayment Facility drawdown
January 2, 2024
Initial overseas orders of MT-RNR1 ID kit
December 20, 2023
MT-RNR1 ID kit adopted for routine use in Brighton
December 4, 2023
Block listing Interim Review
November 30, 2023
c£1.2m grant awarded
September 28, 2023
Application for listing & total voting rights
September 21, 2023
Board changes
September 11, 2023
UKCA marking achieved for new CYP2C19 test
September 6, 2023
Multi-partner grant awarded
June 16, 2023
NICE recommends CYP2C19 genotyping
May 19, 2023
Block Listing Application to AIM
May 15, 2023
£5 million Equity Prepayment Facility
March 31, 2023
Price Monitoring Extension
March 30, 2023
Commence of roll out in Greater Manchester
March 20, 2023
Second Price Monitoring Extn
February 9, 2023
Notice of AGM
December 5, 2022
Block Listing Six Monthly Return
November 30, 2022
Audited Final Results
November 21, 2022
Grant of options
October 24, 2022
US FDA pre-submission for Genedrive MT-RNR1 kit
October 5, 2022